台灣醫療產業之產學合作成功模式 —以台大創新藥物中心為個案

The Successful Model of Collaboration between Academia and Corporation for Medical Industry in Taiwan – Case study: Center for Innovative Therapeutics Discovery, National Taiwan University

王雅俊(Ya-Chun Wang)

指導教授 ： 陸洛

國立臺灣大學/管理學院/商學組/碩士(2014年)

https://doi.org/10.6342/NTU.2014.00047

摘要

目前由學、研界成功由產業界承接的創新藥物很有限，學、研界所投入的人力、經費、資源等應能為台灣的產業界提供非常優質的創新藥物，應能為台灣的產業界提供非常優質的創新藥物標的，然後協助台灣建立可立足於國際與國際競爭的生技新藥產業。台大創新藥物中心應契合於其使命，建立一個邁向永續發展平台，作為新藥探索與商業化間的橋樑，其首要任務，一是建立永續發展平台，就是建立創新藥物中心本身的核心技術、核心能力、核心資源及整合資源。另一是新藥探索與商業化間的橋樑，如何配合產業界建立產業界所需的核心能力和資源，如何篩選可以讓產業界承接的新藥標的，如何替產業界培育及訓練跨領域的人才，將是成功推動產學合作的重要方向。
創新藥物中心應針對台灣現有的優勢及國際競爭力，與國際大藥廠或生技公司的方向，做一評估，選出於台灣有優勢且不是國際大藥廠或生技公司競爭的焦點，當成是創新藥物中心核心技術、核心能力、核心資源建立的起始，而這台灣優勢可從醫療的領域、疾病的罹病率、治療的迫切性及unmet clinical needs去評估，就如華人特有疾病，病毒性肝炎或肝癌等。
創新藥物中心如何於研發組織、策略之訂定，成為台灣醫療產業的催生者且為之堅強後盾，契合產業之需求，創造產學合作的成功模式，成為台灣學術界與產業界的典範。

關鍵字

產學合作 ； 新藥產業 ； 創新藥物 ； 學術界研發成果 ； 研發管理及激勵

並列摘要

The collaboration and technical transfer between academic and industry are lack of successful case currently. Supposedly, the human capital, grants and resources invested from academic and RD institute should have the ability to provide a superior innovative new drug candidate for industry to develop in the second stage. This collaboration should help Taiwan’s biotech industry to stand out and meet the challenges in global market. The Center for Innovative Therapeutics Discovery (CITD), NTU has the vision, purpose and goal to establish the platform for long term development to be the bridge of new drug discovery and business development. The major tasks are two. First, CITD should establish the platform of core technology, core ability, core resources, and integration of resources for the discovery of innovative new drug. Second, CITD should be the bridge of academic and industry to establish the core technology and resources based on the needs of industry in Taiwan. How to screen the new drug leading compounds and train the professional skills for industry to use in the second stage should be the most important direction of CITD to push and promotion.
Based on the diseases and unmet clinical needs evaluation, CITD could establish the core technology, ability, and resource on the fields with the challenging strength and professional skill in Taiwan, not the fields of big pharmaceutical company’s focus. For example, the live diseases HBV, HCC are the major problem for Chinese to be treated. CITD can create a standardized model for the collaboration of academic and industry to become the successful model meeting the needs of industry on Taiwan based on its unique RD structure, strategies, and core technology.

並列關鍵字

Collaboration of academic and Industry ； innovative new drug ； RD management and inspiration

參考文獻

10. 陳淑君、陳殷哲（2013）知識密集型產業員工激勵因素與工作壓力關聯性之探討。就業與勞動關係季刊，3(1)，63–76

6. Jing Zhang, Charles Baden-Fuller and Vincent Mangematin (2007) Technological Knowledge Base, R&D Organization Structure and Alliance

8. 周燦德, (2013) 台灣推動產學合作的策略模式- 產學研發與人才培育, 朝陽學報第18期: 85-109

1. Agarwal, R., Ganco, M., & Ziedonis, R. H. (2009) Reputations for toughness in patent enforcement: Implications for knowledge spillovers via inventor mobility. Strategic Management Journal, 30: 1349-1374.

2. Ashish Arora, Sharon Belenzon and Luis A. Rios (2012) Make, Buy, Organize: The interplay between R&D, external knowledge, and firm structure.